Treatment of intermediate unfavorable, high- and very-high risk prostate cancer with SBRT: a multi-institutional analysis
This content is only accessible to Accuray Exchange (AEx) members. Username Password Remember Me Forgot Password
Initial experience of Radixact® Synchrony® tracking on cancer in prostate and lung
This content is only accessible to Accuray Exchange (AEx) members.
SBRT for High-Risk Prostate Cancer
This content is only accessible to Accuray Exchange (AEx) members.
17 years of CyberKnife® System SBRT for Prostate Cancer
This content is only accessible to Accuray Exchange (AEx) members.
What We Have Learnt from PACE Multicenter, International Phase 3 Randomized Controlled Study
This content is only accessible to Accuray Exchange (AEx) members.
Prostate SBRT and the PACE-B Trial
Alison Tree, MBBS, BSc, FRCR, M.D.(Res) | Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK | ASTRO 2022 AEx Academy
Clinical Value of Motion Synchronization for Prostate SBRT
Sean Collins, M.D., Ph.D. | MedStar Georgetown University Hospital, Georgetown University School of Medicine, Washington, D.C. | ASTRO 2022 AEx Academy
Long-Term Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
This content is only accessible to Accuray Exchange (AEx) members.
Stereotactic Body Radiation Therapy in Treating Patients with Oligo-metastatic Hormone-Naïve Prostate Cancer
This content is only accessible to Accuray Exchange (AEx) members.
Primary prostate cancer, unfavorable, high risk prostate cancer, relapsed and oligometastatic prostate cancer
This content is only accessible to Accuray Exchange (AEx) members.